Summary

For patients with inoperable severe aortic stenosis, the incremental cost per life-year gained for transcatheter aortic valve replacement is in line with values for other cardiovascular technologies. This article presents these findings, which are based on a cost-effectiveness study of the PARTNER trial (Cohort B).